GlassScriptPhysician profile
Gregory L Glance
NPI 1386610632
$11,266.75
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,322 · 2020: $1,600 · 2021: $2,410 · 2022: $2,636 · 2023: $2,300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,299.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,193.29 | 2019-2023 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $1,163.96 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $871.02 | 2019-2023 | Mounjaro, Trulicity, Jardiance |
| Pfizer INC. | $864.45 | 2019-2023 | |
| Glaxosmithkline, LLC. | $786.28 | 2019-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Abbvie INC. | $692.28 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $677.38 | 2019-2023 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $577.64 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $504.28 | 2019-2022 | |
| Amgen INC. | $481.05 | 2019-2023 | Otezla, Repatha, Evenity |
| Amarin Pharma, INC. | $401.65 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $391.60 | 2019-2023 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $371.20 | 2019-2023 | Breztri, Farxiga |
| Sanofi-Aventis U.S. LLC | $315.19 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $285.36 | 2019-2023 | Verquvo, Belsomra, Steglatro |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Glance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.